Publicaciones científicas

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

15-ene-2021 | Revista: Clinical Cancer Research

Martin Gutierrez  1 , Victor Moreno  2 , Kimberley M Heinhuis  3 , Anthony J Olszanski  4 , Anna Spreafico  5 , Michael Ong  6 , Quincy Chu  7 , Richard D Carvajal  8 , José Trigo  9 , Maria Ochoa de Olza  10 , Mariano Provencio  11 , Filip Yves De Vos  12 , Filippo De Braud  13 , Stephen Leong  14 , Deanne Lathers  15 , Rui Wang  15 , Palani Ravindran  15 , Yan Feng  15 , Praveen Aanur  15 , Ignacio Melero  16

Purpose: This phase I/IIa study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist IgG1 mAb, ± nivolumab and/or ipilimumab in patients with advanced solid tumors.

Patients and methods: Patients (with non-small cell lung, renal cell, bladder, other advanced cancers) received BMS-986178 (20-320 mg) ± nivolumab (240-480 mg) and/or ipilimumab (1-3 mg/kg). The primary endpoint was safety. Additional endpoints included immunogenicity, pharmacodynamics, pharmacokinetics, and antitumor activity per RECIST version 1.1.

Results: Twenty patients received BMS-986178 monotherapy, and 145 received combination therapy in various regimens (including two patients receiving nivolumab monotherapy). With a follow-up of 1.1 to 103.6 weeks, the most common (≥5%) treatment-related adverse events (TRAEs) included fatigue, pruritus, rash, pyrexia, diarrhea, and infusion-related reactions.

Overall, grade 3-4 TRAEs occurred in one of 20 patients (5%) receiving BMS-986178 monotherapy, six of 79 (8%) receiving BMS-986178 plus nivolumab, zero of two receiving nivolumab monotherapy, six of 41 (15%) receiving BMS-986178 plus ipilimumab, and three of 23 (13%) receiving BMS-986178 plus nivolumab plus ipilimumab.

No deaths occurred. No dose-limiting toxicities were observed with monotherapy, and the MTD was not reached in either the monotherapy or the combination escalation cohorts. No objective responses were seen with BMS-986178 alone; objective response rates ranged from 0% to 13% across combination therapy cohorts.

Conclusions: In this study, BMS-986178 ± nivolumab and/or ipilimumab appeared to have a manageable safety profile, but no clear efficacy signal was observed above that expected for nivolumab and/or ipilimumab.

CITA DEL ARTÍCULO  Clin Cancer Res. 2021 Jan 15;27(2):460-472.
doi: 10.1158/1078-0432.CCR-20-1830. Epub 2020 Nov 4.